We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-1.03%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$438M
AUM Growth
-$21.2M
Cap. Flow
+$25.3M
Cap. Flow %
5.78%
Top 10 Hldgs %
58.99%
Holding
62
New
9
Increased
15
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$17.2M
2
CYTK icon
Cytokinetics
CYTK
+$12M
3
CRGX
CARGO Therapeutics
CRGX
+$10.6M
4
JBIO
Jade Biosciences
JBIO
+$8.34M
5
ARVN icon
Arvinas
ARVN
+$7.17M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.83M
2
OCUL icon
Ocular Therapeutix
OCUL
+$8.31M
3
CMPX icon
Compass Therapeutics
CMPX
+$6.28M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$5.67M
5
NYXH
Nyxoah
NYXH
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 98.24%
2 Miscellaneous 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTX icon
51
Context Therapeutics
CNTX
$38.2M
– –
-1,108,357
Closed -$1.53M
CRNX icon
52
Crinetics Pharmaceuticals
CRNX
$9B
– –
-210,000
Closed -$9.83M
GKOS icon
53
Glaukos
GKOS
$10.7B
– –
-8,576
Closed -$809K
LRMR icon
54
Larimar Therapeutics
LRMR
$421M
– –
-174,413
Closed -$1.32M
NYXH
55
Nyxoah
NYXH
$160M
– –
-320,000
Closed -$4.32M
PGEN icon
56
Precigen
PGEN
$2.57B
– –
-947,500
Closed -$1.37M
RPTX
57
DELISTED
Repare Therapeutics
RPTX
– –
-67,561
Closed -$318K
ZNTL icon
58
Zentalis Pharmaceuticals
ZNTL
$367M
– –
-200,000
Closed -$3.15M
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-785,000
Closed -$3.86M
MOR
60
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-65,000
Closed -$1.18M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2024 Portfolio in Review

As of Q2 2024, Opaleye Management held 62 positions worth $438M, down 4.6% from $459M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management deployed $25.3M of net new capital in Q2 2024, opening 9 new positions and adding to 15 existing holdings. Its largest new stake was Immunome: 1,102,500 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $8.31M trimmed.

  • Opaleye Management's largest Q2 2024 buy was Immunome: 1,102,500 shares worth $13.3M.
  • Opaleye Management added most to Arvinas in Q2 2024, an estimated $7.17M increase.
  • Opaleye Management's biggest Q2 2024 reduction was Ocular Therapeutix, cutting an estimated $8.31M.
  • Opaleye Management fully exited Crinetics Pharmaceuticals in Q2 2024, selling an estimated $9.83M.
  • Opaleye Management's ten largest holdings make up 59% of its $438M portfolio in Q2 2024.
  • Opaleye Management opened 9 new positions and closed 11 in Q2 2024.
  • Opaleye Management's portfolio value fell 4.6% quarter-over-quarter to $438M.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.